Abstract:Background: For the past 20 years, twice-daily thoracic radiotherapy with concurrent chemotherapy has been the treatment of choice for limited-stage small-cell lung cancer (LS-SCLC), which has a poor prognosis. We aimed to assess the efficacy and safety of high-dose, accelerated, hyperfractionated, twice-daily thoracic radiotherapy (54 Gy in 30 fractions) versus standard-dose radiotherapy (45 Gy in 30 fractions) as a first-line treatment for LS-SCLC. Methods: This open-label, randomised, phase 3 trial was performed at 16 public hospitals in China. The key inclusion criteria were patients aged 18-70 years, with histologically or cytologically confirmed LS-SCLC, who had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and who were previously untreated or had received one course of cisplatin or carboplatin and etoposide. Eligible patients were randomly assigned (1:1) to receive volumetric-modulated arc radiotherapy (VMAT) of 45 Gy in 30 fractions to the gross tumour volume or VMAT with a simultaneous integrated boost of 54 Gy in 30 fractions to the gross tumour volume starting 0-42 days after the first chemotherapy course. Both groups received 10 fractions of twice-daily thoracic radiotherapy per week. The planning target volume was 45 Gy in 30 fractions in both groups. Patients with responsive disease received prophylactic cranial radiotherapy (25 Gy in 10 fractions). Randomisation was performed using a centralised interactive web response system, stratified by ECOG performance status, disease stage, previous chemotherapy course, and chemotherapy choice. The primary outcome was overall survival in the intention-to-treat population. Safety was analysed in the as-treated population. This study was registered at ClinicalTrials.gov, NCT03214003. Findings: From June 30, 2017, to April 6, 2021, 224 patients (102 [46%] females and 122 [54%] males; median age 64 years [IQR 58-68]) were enrolled and randomly assigned to the 54 Gy group (n=108) or 45 Gy (n=116) group. The median follow-up was 46 months (IQR 33-56). The median overall survival was significantly longer in the 54 Gy group (60·7 months [95% CI 49·2-62·0]) than in the 45 Gy group (39·5 months [27·5-51·4]; hazard ratio 0·55 [95% CI 0·37-0·72]; p=0·003). Treatment was tolerable, and the chemotherapy-related and radiotherapy-related toxicities were similar between the groups. The grade 3-4 radiotherapy toxicities were oesophagitis (14 [13%] of 108 patients in the 54 Gy group vs 14 [12%] of 116 patients in the 45 Gy group; p=0·84) and pneumonitis (five [5%] of 108 patients vs seven [6%] of 116 patients; p=0·663). Only one treatment-related death occurred in the 54 Gy group (myocardial infarction). The study was prematurely terminated by an independent data safety monitoring board on April 30, 2021, based on evidence of sufficient clinical benefit. Interpretation: Compared with standard-dose thoracic radiotherapy (45 Gy), high-dose radiotherapy (54 Gy) improved overall survival without increasing toxicity in a cohort of patients aged 18-70 years with LS-SCLC. Our results support the use of twice-daily accelerated thoracic radiotherapy (54 Gy) with concurrent chemotherapy as an alternative first-line LS-SCLC treatment option. Funding: Chinese Society of Clinical Oncology-Linghang Cancer Research, the Wu Jieping Medical Foundation, and Clinical Research Fund For Distinguished Young Scholars of Peking University Cancer Hospital and Beijing Municipal Administration of Hospitals Incubating Program.

MA 01.11 Timing of Thoracic Radiotherapy is More Important Than Dose Escalation in Patients with Limited-Stage Small Cell Lung Cancer

Effects of hyperfractionated radiotherapy versus hypofractionated radiotherapy combined with concurrent chemotherapy on prognosis of limited-stage small-cell lung cancer

Analysis of Optimal Dose of Thoracic Radiotherapy for Patients with Extensive Stage Small Cell Lung Cancer

Efficacy and Safety of High Dose Twice-Daily Thoracic Radiotherapy Versus Standard Dose for Limited Stage Small-Cell Lung Cancer: A Multicentre, Open-Label Randomised, Phase 3 Trial

Effects of Thoracic Radiotherapy Timing and Duration on Progression‐free Survival in Limited‐stage Small Cell Lung Cancer

Comparison of efficacy of different fractionation schedules in radiotherapy for extensive-stage small cell lung cancer

Final report of a prospective randomized study on thoracic radiotherapy target volumes for limited-stage small cell lung cancer

Timing of Thoracic Radiotherapy in the Treatment of Extensive-Stage Small-Cell Lung Cancer: Important or Not?

The effect of dose fractionation on overall survival in patients with limited-stage small cell lung cancer

Receipt of Thoracic Radiation Therapy and Radiotherapy Dose Are Correlated with Outcomes in a Retrospective Study of Three Hundred and Six Patients with Extensive Stage Small-Cell Lung Cancer.

The Effect of Bioequivalent Radiation Dose with Treatment Time on Survival of Limited-stage Small–cell Lung Cancer

Clinical Outcomes and Prognostic Factors in Limited-Stage Small Cell Lung Cancer Patients Treated with Intensive Modified Radiation Therapy

OA13.06 Final Report of a Prospective Randomized Study on Thoracic Radiotherapy Target Volumes with Radiation Dosimetric and Pathologic Analyses

Biologically Effective Dose-response Relationship for Patients with Limited-stage Small-cell Lung Cancer Treated with Combined Radiotherapy and Chemotherapy

Phase 2 Study of Accelerated Hypofractionated Thoracic Radiation Therapy and Concurrent Chemotherapy in Patients with Limited-Stage Small-Cell Lung Cancer.

Effects of different chemoradiotherapy schemes on the prognosis of extensive-stage small-cell lung cancer

High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial

Increased Biological Effective Dose of Radiation Correlates with Prolonged Survival of Patients with Limited-Stage Small Cell Lung Cancer: A Systematic Review.

[Analysis of risk factors of radiation-induced toxicity in limited-stage small cell lung cancer treated with hypofractionated intensity-modulated radiotherapy]

Hypofractionated Stereotactic Radiation Therapy for Advanced Non-Small Cell Lung Cancer: Report on Clinical Outcome and Toxicity

Final Report of a Prospective Randomized Study on Thoracic Radiotherapy Target Volume for Limited-Stage Small Cell Lung Cancer with Radiation Dosimetric Analyses